Abstract:The development of efficient galectin-3 (Gal-3) inhibitors draws attention in the field of anti-cancer therapy, especially due to the prominent role of extra- and intracellular Gal-3 in vital processes of cancerogenesis, such as immunosuppression, stimulation of tumor cells proliferation, survival, invasion, apoptotic resistance, and metastasis formation and progression. Here, by combining poly-LacNAc (Galβ4GlcNAc)-derived oligosaccharides with N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers, we synthesized multivalent glycopolymer inhibitors with a high potential to target extracellular and intracellular Gal-3. The inhibitory capabilities of the best conjugate in the studied series were in the nanomolar range proving the excellent Gal-3 inhibitory potential. Moreover, thorough investigation of the inhibitory effect in the biological conditions showed that the glycopolymers strongly inhibited Gal-3-induced apoptosis of T lymphocytes and suppressed migration and spreading of colorectal, breast, melanoma, and prostate cancer cells. In sum, the strong inhibitory activity toward Gal-3, combined with favorable pharmacokinetics of HPMA copolymers ensuring enhanced tumor accumulation via the enhanced permeability and retention effect, nominate the glycopolymers containing LacdiNAc-LacNAc (GalNAcβ4GlcNAcβ3Galβ4GlcNAc) tetrasaccharide as promising tools for preclinical in anti-cancer therapy evaluation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.biomac.0c00515?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.biomac.0c00515</a>.Analytical methods; synthesis of functionalized carbohydrate ligands; MS spectra of functionalized carbohydrate ligands; detailed synthesis of polymer precursor 6; detailed synthesis of glycopolymer 17; characterization of polymer precursors and glycopolymers; NMR spectra of glycopolymers 9, 12, and 17; inhibition of Gal-3 binding by glycopolymers; and Gal-3 expression in cancer cell lines (<a class="ext-link" href="/doi/suppl/10.1021/acs.biomac.0c00515/suppl_file/bm0c00515_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Galectin-3 inhibitors: a patent review (2008–present)

An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)

Inhibition of Galectins with Small Molecules

Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update

Galectin-3: therapeutic targeting in liver disease

New clues arising from hunt of saccharides binding to galectin 3 via 3D QSAR and docking studies

A Selective Galactose–Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model

Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis

Glycopolymers for Efficient Inhibition of Galectin-3: In Vitro Proof of Efficacy Using Suppression of T Lymphocyte Apoptosis and Tumor Cell Migration

Dissecting the Structure–Activity Relationship of Galectin–Ligand Interactions

Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease

Identification of benzothiazole derived monosaccharides as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3; a rare example of using a S···O binding interaction for drug design

Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient

Targeting galectin-3 by natural glycosides: a computational approach

Galectin-3 in Cardiovascular Diseases

Drug repurposing against galectin-3 using simulation-based studies

Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver

Galectin–Carbohydrate Interactions in Biomedicine and Biotechnology

Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1

Design and synthesis of novel coumarin–benzimidazole hybrids as human galectin-1 inhibitors